Giant cell arteritis after the age of 75;Maladie de horton chez le sujet âgé de plus de 75 ans

Annales de Medecine Interne

Volumn 153, Issue 6, 2002, Pages 373-377

  Chevalet, Pascal ^a   Masseau Imbert, Agathe ^a   Durand Fix, Marie Hélène ^a   Agard, Christian ^a   Brisseau, Jean Marie ^a   Rodat, Olivier ^a   Barrier, Jacques Henri ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Corticosteroid induced osteoporosis; Elderly; Giant cell arteritis; Treatment

Indexed keywords

ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; PREDNISONE;

AGED; BLINDNESS; DOSE RESPONSE; DRUG USE; FRACTURE; GERIATRIC DISORDER; GIANT CELL ARTERITIS; HUMAN; ISCHEMIA; OSTEOPOROSIS; REVIEW; SENESCENCE; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG MONITORING; FEMALE; FRAIL ELDERLY; HEPARIN; HUMANS; MALE; OSTEOPOROSIS; PREDNISONE; TEMPORAL ARTERITIS;

EID: 0036816664     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Hunder GG: Giant cell arteritis: A disease of the elderly. Geriatrics, 1983; 38: 55-64.
2. Emmerich J, Fiessinger JN: Épidémiologie et facteurs étiologiques des artérites à cellules géantes (maladie de Horton et maladie de Takayasu). Ann Med Interne, 1998; 149: 425-32.
3. Chevalet P, Barrier JH, Pottier P, et al.: A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year follow-up study of 164 patients. J Rheumatol, 2000; 27: 1484-91.
4. Barrier JH, Chevalet P, Ponge T: Les principes du traitement d'attaque de la maladie de Horton. Place des assauts cortisoniques. Ann Med Interne, 1998; 149: 448-53.
5. Chevalet P, Barrier JH, Glemarec J, et al.: Maladie de Horton du sujet âgé de plus de 75 ans: Particularités évolutives, complications de la corticothérapie. Étude comparative sur une série de 164 patients. Vers une dose d'attaque réduite. Rev Med Interne, 2001; 22: 624-30.
6. Bengtsson BA, Malmvall BE: The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica: Incidences of different clinical presentations and eye complications. Arthritis Rheum, 1981; 24: 899-904.
7. Machado EB, Michet CJ, Ballard DJ, et al.: Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum, 1988; 31: 745-9.
8. Ostberg G: An arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand [A], 1973; 237: 237-59.
9. Mason JC, Walport MJ: Giant cell arteritis. BMJ, 1992; 305: 68-9.
10. Ly K, Liozon E, Debrock C, et al.: Maladie de horton du sujet âgé: Étude prospective de 181 patients [Abstract]. Rev Med Interne, 2000; 21 (suppl 2): 190.
11. Perruquet JL, Davis DE, Harrington TM: Aortic arch arteritis in the elderly. An important manifestation of giant cell arteritis. Arch Intern Med, 1986; 146: 289-91.
12. Allison MC, Gough KR: Steroid sensitive systemic disease with anaemia in the elderly: A manifestation of giant cell arteritis? Postgrad Med J. 1985; 61: 501-3.
13. Liozon F: La maladie de horton. Ann Med Interne, 1989; 140: 122-41.
14. Liozon E, Herrmann FR, Ly K, et al.: Facteurs prédictifs de complications céphaliques ischémiques irréversibles au cours de la maladie de horton: Étude prospective sur 178 patients. Rev Med Interne, 2001; 22: 30-41.
15. Kyle V, Hazleman BL: Treatment of polymyalgia rheumatica and giant cell arteritis. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis, 1989; 48: 662-6.
16. Lundberg I, Hedfors E: Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol, 1990; 17: 1340-5.
17. Nesher G, Sonnenblick M, Friedlander Y: Analysis of steroid related complications and mortality in temporal arteritis: A 15-year survey of 43 patients. J Rheumatol, 1994; 21: 1283-6.
18. Thomas TPL: The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology, 1984; 30: 60-5.
19. Behn AR, Perera T, Myles AB: Polymyalgia rheumatica and corticosteroids: How much for how long? Ann Rheum Dis, 1983; 42: 374-8.
20. Genereau t, Cabane J: Bénéfice des corticoïdes lors du traitement de la maladie de horton et de la pseudo-polyarthrite rhizomélique: Avantages et inconvénients. Une méta-analyse. Rev Med Interne, 1992; 13: 387-91.
21. Robb-Nicholson C, Chang RW, Anderson S, et al.: Diagnostic value of the history and examination in giant cell arteritis: A clinical pathological study of 81 temporal artery biopsies. J Rheumatol, 1988; 15: 1793-6.
22. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN: Vertebral fracture risk with long-term corticosteroid therapy. Prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med, 2000; 160: 2917-22.
23. Nesher G, Rubinow A, Sonnenblick M: Efficacy and adverse effects of different corticosteroid dose regimen in temporal arteritis: A retrospective study. Clin Exp Rheumatol, 1997; 15: 303-6.
24. Liozon F, Vidal E, Gaches F, et al.: Les décès dans la maladie de horton. Facteurs de pronostic. Rev Med Interne, 1992; 13: 187-91.
25. Barrier JH, Magadur-Joly G: Aspects actuels de la corticothérapie au long cours chez les personnes âgées. L'exemple de la maladie de horton. Ann Med Interne. 1994; 145 (suppl 2): 29-33.
26. Myles AB, Perera T, Ridley MG: Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol, 1992; 31: 103-5.
27. Andersson R, Malmvall BE, Bengtsson BA: Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids. Acta Med Scand, 1986; 220: 361-4.
28. Bengtsson BA, Malmvall BE: Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Acta Med Scand, 1981; 209: 337-45.
29. Save-Söderbergh J, Malmvall BE, Andersson R, Bengtsson BA: Giant cell arteritis as a cause of death. Report of nine cases. JAMA, 1986; 255: 493-6.
30. Hachulla E, Boivin V, Pasturel-Michon U, et al.: Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol, 2001; 19: 171-6.
31. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B: Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2001; 134: 106-14.
32. Evans J, Hunder GG: The implications of recognizing large-vessel involvement in elderly patients with giant cell arteritis. Curr Opin Rheumatol, 1997; 9: 37-40.
33. Staunton H, Stafford F, Leader M, O'Riordain D: Deterioration of giant cell arteritis with corticosteroid therapy. Arch Neurol, 2000; 57: 581-4.
34. Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum, 2001; 44: 202-11.
35. Adachi JD, Olszynski WP, Hanley DA, et al.: Management of corticosteroid-induced osteoporosis. J Semin Arthritis Rheum, 2000; 29: 228-51.
36. Orcel P, Roux C: Ostéoporose cortisonique. Rev Rhum, 2001; 68: 678-84.